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Astrocytoma is the most common type of brain cancer
constituting more than half of all brain tumors. With an
aim to identify markers describing astrocytoma progres-
sion, we have carried out microarray analysis of astro-
cytoma samples of different grades using cDNA
microarray containing 1152 cancer-specific genes. Data
analysis identified several differentially regulated genes
between normal brain tissue and astrocytoma as well as
between grades II/III astrocytoma and glioblastoma
multiforme (GBM; grade IV). We found several genes
known to be involved in malignancy including Achaete-
scute complex-like 1 (Drosophila) (ASCL1; Hash 1). As
ASCL has been implicated in neuroendocrine, medullary
thyroid and small-cell lung cancers, we chose to examine
the role of ASCL1 in the astrocytoma development. Our
data revealed that ASCL1 is overexpressed in progressive
astrocytoma as evidenced by increased levels of ASCL1
transcripts in 85.71% (6/7) of grade II diffuse astro-
cytoma (DA), 90% (9/10) of grade III anaplastic
astrocytoma (AA) and 87.5% (7/8) of secondary GBMs,
while the majority of primary de novo GBMs expressed
similar to or less than normal brain levels (66.67%; 8/12).
ASCL1 upregulation in progressive astrocytoma is
accompanied by inhibition of Notch signaling as seen by
uninduced levels of HES1, a transcriptional target of
Notch1, increased levels of HES6, a dominant-negative
inhibitor of HES1-mediated repression of ASCL1, and
increased levels of Notch ligand Delta1, which is capable
of inhibiting Notch signaling by forming intracellular
Notch ligand autonomous complexes. Our results imply
that inhibition of Notch signaling may be an important
early event in the development of grade II DA and
subsequent progression to grade III AA and secondary
GBM. Furthermore, ASCL1 appears to be a putative
marker to distinguish primary GBM from secondary
GBM.
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Introduction
Astrocytomas are the most common primary brain
tumors and occur at an incidence of almost 12 per
100 000 people (Landis et al., 1999). Diffuse astrocyto-
ma (DA) may be classified (as per WHO classification)
as low-grade DA (grade II), anaplastic astrocytoma
(AA; grade III) and glioblastoma multiforme (grade IV;
GBM), in the order of increasing malignancy (Mischel
and Vinters, 2001). Currently, these classifications are
based on the observed histopathological characteristics
of the tumor, which are sometimes subjective and
inconsistent. GBM constitutes more than 80% of
malignant gliomas (DeAngelis, 2001) and patients with
GBM have a median survival of less than 1 year.
Current treatments, including surgery, radiation ther-
apy, and chemotherapy, unfortunately have not chan-
ged the natural history of these incurable neoplasms;
and the prognosis of patients with GBMs has not
improved significantly in the past 30 years (Davis et al.,
1998). To find new diagnostic and therapeutic strategies,
a better understanding of the biological pathway(s)
leading to glial tumorigenesis is warranted.
Astrocytoma development is known to involve
accumulation of a series of genetic alterations (Nagane
et al., 1997) similar to other cancers. Identification of
many of the genes involved in the astrocytoma deve-
lopment, using standard molecular approaches, has
helped to understand the process of astrocytoma genesis
and progression (Louis and Gusella, 1995). Frequent
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amplification of epidermal growth factor receptor
(EGFR) (Brock and Bower, 1997; Hill et al., 1999),
platelet-derived growth factor receptor (Maxwell et al.,
1990; Fleming et al., 1992; Hermanson et al., 1992, 1996;
Westermark et al., 1995), amplification of chromosome
12q region, which carries the cdk4 gene (Nagane et al.,
1997; Hill et al., 1999) and alterations in chromosomes
1p, 9p, 10, 17p, 19q and 22q, have frequently been found
in these tumors. In addition, mutations in the tumor
suppressor gene p53 were found to be associated with
chromosome 17p alterations in low-grade and progres-
sive astrocytoma (Maher et al., 2001; Phatak et al.,
2002). Inactivation of the cdk inhibitor p16INK4a residing
in chromosome 9p is very common in sporadic
astrocytoma, occurring in 50–70% of high-grade glio-
mas and 90% of GBM cell lines (James et al., 1991;
Olopade et al., 1992). LOH in chromosome 10 is one of
the most frequent alterations in GBM and is accom-
panied by the loss of PTEN/MMAC gene (Li et al.,
1997; Hill et al., 1999).
GBMs are of two types: primary GBM (de novo type),
which manifests in older patients (mean age: 55 years) as
an aggressive, highly invasive tumor, usually without
any evidence of prior clinical disease, after a short
clinical history of approximately less than 3 months, and
secondary GBM (progressive type) is usually seen in
younger patients (mean age: 40 years) and develops
more slowly by malignant progression from DA (WHO
grade II) or AA (WHO grade III). Although some
differences in the genetic alterations between these two
GBMs have been identified, they are not sufficient
enough to be used as differentiating markers considering
the fact that the two types of GBMs have almost
comparable clinical, genetic and biological character-
istics (Kleihues et al., 2002). However, it is likely that
these subtypes would respond differently to specific
novel therapies as they are developed in the future
(Kleihues and Ohgaki, 1999).
Despite all this information, our understanding of
astrocytoma development is not sufficient enough to
improve prognosis for GBM patients. A more global,
systematic understanding of expression patterns of
various genes and their downstream gene products in
astrocytoma will hopefully provide new diagnostic and
therapeutic targets. Towards this, a number of studies
have reported the gene expression profile of astrocytoma
(Liau et al., 2000; Sallinen et al., 2000; Ljubimova et al.,
2001; Rickman et al., 2001; Watson et al., 2001;
Fathallah-Shaykh et al., 2002; Tanwar et al., 2002;
Godard et al., 2003; Nutt et al., 2003; Wang et al., 2003).
In this study, we used cDNA microarrays containing
1152 genes to study the expression profile of DA. By
using hierarchical cluster analysis, we have identified
several genes that are differentially expressed between
normal brain tissue and astrocytoma as well as between
grade II/III astrocytomas and GBMs. A novel finding
was that the elevated expression of Achaete-scute
complex-like 1 (Drosophila) (ASCL1) and simultaneous
inhibition of Notch signaling pathway describes the
development and further progression of grade II DA to
grade III AA and then to secondary GBM. Finally, we
propose that ASCL1 could be used as a marker to
differentiate secondary GBMs from primary GBMs.
Results
Hierarchical clustering of the complete data set
We have used microarray slides containing 1152 cancer-
related genes in duplicate (GeneMAPTM Human Cancer
Array) obtained from Genomic Solutions Inc. A total of
seven tumor samples comprising three grade II/III
astrocytomas and four GBMs (grade IV) were analysed.
The 459 genes that had values in at least two samples in
each group were used for further analysis. The normal-
ized and log 2-transformed data containing values for
these genes were subjected to an unsupervised, two-way,
average-linkage hierarchical cluster analysis with un-
centered correlation coefficient as similarity metric,
using the Gene Cluster software. The Java TreeView
software was used to display and analyse the results of
the Gene Cluster program (Figure 1). This was carried
out to see whether the two groups – grade II/III astro-
cytoma and GBMs (IV) – show distinct patterns of gene
expression. The sample dendrogram clearly separates
into two main branches: one consisting of grade II/III
samples and other consisting of GBMs, exemplifying the
inherent differences between them. In addition, genes
with similar expression profiles were grouped together.
Four clusters A, B, C and D were noteworthy (Figure 1).
The cluster A essentially consists of genes upregulated in
all grades of astrocytomas and the cluster B essentially
consists of genes downregulated in all grades of astro-
cytomas. The other two clusters (C and D) consist of
genes, which are differentially expressed between grade
II/III astrocytomas and GBMs (Figure 1). The cluster C
essentially consists of genes that are upregulated in grade
II/III astrocytomas compared to GBMs. The cluster D
consists of genes that are downregulated in grade II/III
astrocytomas compared to GBMs (Figure 1).
Real-time quantitative RT–PCR analysis of selected
genes
In our study, Osteonectin, an acidic, cysteine-rich,
secreted protein (SPARC), was upregulated in majority
of all grades of astrocytoma (grade II/III – 89% (8/9);
secondary GBMs (IV) – 75% (3/4); primary GBMs (IV) –
91.7% (11/12); data not shown). Vimentin, a cytoskeleton
protein, was also found upregulated in majority samples
of all grades of astrocytomas (grade II/III – 70% (7/10);
secondary GBMs (IV) – 100% (4/4); primary GBMs (IV)
– 91.7% (11/12); data not shown). In addition, we
identified b2-microglobulin to be upregulated more than
1.5-fold compared to normal brain samples in majority
of GBMs (grade II/III – 27.2% (3/11); secondary GBMs
– 66.67% (4/6) and primary GBMs (IV) – 100% (12/12);
data not shown). Further, we found Semaphorin 4D
(CD100) to be downregulated in astrocytomas, particu-
larly in the majority of primary GBMs (grade II/III –
44.4% (4/9); secondary GBMs (IV) – 25% (1/4); primary
GBMs (IV) – 80% (12/15); data not shown).
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Differential regulation of ASCL1 distinguishes between
primary and secondary GBM
We found the ASCL1 to be an attractive candidate as it
is differentially regulated in progressive astrocytoma
(see below). ASCL1 has been shown to be highly
expressed in neuroendocrine (NE) cancers, medullary
thyroid cancer and small-cell lung cancer (Ball et al.,
1993). We found ASCL1 to be upregulated in majority
of grade II DAs (85.71%; 6/7), grade III AA (90%;
9/10) and secondary GBMs (87.5%; 7/8) (Figure 2a).
However, among primary GBMs, ASCL1 upregulation
was seen only in 33.33% (4/12) of the samples
(Figure 2a). Increase in ASCL1 transcripts also correlated
immunohistochemically with increased nuclear staining
for ASCL1 in grade II DA (Figure 3d), grade III AA
(Figure 3f) and secondary GBM (Figure 3h). Most of
these samples also showed increased nuclear staining for
p53, which is indicative of mutated p53 characterizing
progressive astrocytomas and did not show staining for
EGFR (Table 1). As expected, primary GBMs did not
show detectable staining for ASCL1 (Figure 3j). The
majority of these tumors overexpressed EGFR, while
p53 immunoreactivity was noted in minimal number of
cases (Table 1). Normal brain sections did not reveal
immunoreactivity for ASCL1 (Figure 3), p53 and EGFR
(data not shown). Table 1 describes the details about
various astrocytoma samples used in this study, their
staining pattern for various markers and their clinical
parameters. These results suggest that the ASCL1 expres-
sion could be used to define progressive astrocytoma and
further to differentiate primary from secondary GBMs.
Inhibition of Notch signaling pathway in progressive
astrocytoma
In the central nervous system (CNS), Notch signaling
promotes differentiation of neural stem cells to astro-
glial cell lineage, while simultaneously inhibiting neuro-
genesis and oligodendroglial differentiation (Ge et al.,
2002). Notch signaling causes transactivation of Hairy
and Enhancer of Split (HES) genes, which in turn
repress ASCL1 expression through transcriptional
mechanisms (Chen et al., 1997). Since our results show
that there is upregulation of ASCL1 in the majority of
grade II DA, grade III AA and secondary GBMs, we
hypothesized that Notch signaling may be inhibited
during DA (grade II) development from astroglial cells,
which would further provide suitable environment for
progression to AA (grade III) and subsequently to
secondary GBM. To test this hypothesis, we analysed
the levels of various Notch pathway genes in the same
set of samples. We found that the transcript levels of
the Notch target gene HES1, a transcriptional repressor
of ASCL1, remain similar to or less than that of normal
brain tissue in 52.94% (9/17) of grade II/III astrocytoma
(three out of seven grade II and six out of 10 grade
III samples) and 85.7% (6/7) of secondary GBM
(Figure 2b). Next, we looked at the levels of HES6
another member of the HES family of genes. HES6 has
been shown to antagonize functionally HES1 and relieve
positive bHLH factors like ASCL1 from inhibition by
HES1 (Bae et al., 2000; Gibert and Simpson, 2003). We
found that the level of HES6 transcripts is increased
several fold in the majority of samples from grade II
DA (71.43%; 5/7), grade III AA (66.67%; 6/9) and
secondary GBM (71.43%; 5/7) (Figure 2c). Thus, the
high level of HES6, which is expected to inhibit HES1,
gives another explanation for induced expression of
ASCL1 in majority of grade II/III astrocytomas and
secondary GBMs in addition to inhibition of Notch
signaling as seen by the uninduced levels of HES1.
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Figure 1 Two-way hierarchical clustering of microarray data.
Normalized, log 2-transformed expression ratios of 459 genes from
seven samples (three grade II/III astrocytomas and four GBMs)
were analysed by two-way hierarchical clustering using Gene
Cluster software and results were visualized by TreeView program.
A dual color code was utilized with red and green indicating
up- and downregulation, respectively, in the particular glioma
sample compared to normal brain tissue. Four clusters named A, B,
C, and D are marked. The scale at the bottom shows the
relationship between color saturation and the log 2-transformed
gene expression ratios
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Since Notch receptors get activated upon binding to
their ligands, we then analysed levels of expression of
Notch ligands Delta1 (Delta-like 1; DLL1) and Jagged 1
(JAG1) in astrocytoma samples. The levels of Jagged
1 transcript is found to be upregulated in 57.14% (4/7)
of DA, 40% (4/10) of AA and 42.86% (3/7) of second-
ary GBMs (Figure 2d). Surprisingly, we found very high
levels of Delta1 transcripts in the majority of sam-
ples analysed belonging to grade II DA (71.43%; 5/7),
grade III AA (100%; 10/10) and secondary GBMs
(85.71% 6/7) (Figure 2e). High levels of Delta1 seen in
astrocytoma samples overexpressing ASCL1 can be
explained by the fact that Delta1 is shown to be
transcriptionally activated by ASCL1 (Heitzler et al.,
1996). Increased levels of Notch ligand Delta1 is
expected to activate the Notch signaling pathway. On
the other hand, the presence of uninduced levels of
Notch target gene HES1 and very high levels of ASCL1
transcripts in these samples are suggestive of inhibition
of Notch signaling. As the activity of notch ligands is
known to be regulated by glycosylation of notch
receptors by fringes (Haltiwanger and Stanley, 2002),
we analysed the levels of different fringe molecules in
different grades of astrocytoma. We did not find any
significant change in the expression levels of Lunatic,
Radical and Manic fringe in most samples, suggesting
that fringe molecules may not have any role in inhibiting
notch ligands during progressive astrocytoma develop-
ment (data not shown). It is reported that Notch ligands
Delta1 and Jagged 1 sequester Notch proteins in the
endoreticulum or Golgi apparatus of neuronal precur-
sors as intracellular heteromeric complexes and thus
reduce the effective dose of Notch signaling (Sakamoto
et al., 2002). Thus, the overexpression of Notch ligands
is believed to inhibit Notch signaling by forming
intracellular cell-autonomus ligand : receptor associa-
tions rather than activate the Notch pathway. Taken
together, these results suggest that Notch signaling is
inhibited early during the development of DA and the
consequent elevation of ASCL1 may facilitate further
progression to AA and later to secondary GBM.
In contrast to the above observation, we found no
significant evidence for inhibition of Notch signaling in
primary GBM development. The majority of primary
GBM samples had similar levels of ASCL1 transcripts
to that of normal samples (66.67%; 8/12) (Figure 2a). In
good correlation, the expression of HES1 is increased
in most primary GBM samples (75% had more than
1.5-fold transcripts than that of normal; 9/12) (Figure 2b).
As expected, the levels of HES6 transcripts did not
increase in primary GBMs. The expression levels are in
the same range as normal samples in the majority of them
(75%; 9/12) (Figure 2c). We found the Jagged 1 transcript
levels going up in the majority of primary GBMs
(58.3%; 7/12) (Figure 2d), the significance of which is
not clear at present. The Delta1 transcript levels remain
unchanged in the majority of primary GBMs (91.67%;
11/12) (Figure 2e). These results suggest that Notch
pathway remains activated in primary GBMs and
indicates the possibility that Notch pathway has no role
in the development of primary GBM.
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Figure 2 Scatter plots of differentially regulated Notch pathway
genes during astrocytoma. Log 2-transformed gene expression
ratios obtained from real-time quantitative PCR analysis are
plotted for ASCL1 (a), HES1 (b), HES6 (c), JAG1 (d) and DLL1
(e). Each dot represents a data derived from one sample. A change
in gene expression by twofold or more over its mean expression in
normal brain sample was considered significant
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Figure 3 Immunohistochemical validation of ASCL1 overexpression in progressive astrocytoma. Sections from normal brain (a and
b), grade II DA (c and d), grade III AA (e and f), secondary GBMs (g and h) and primary GBMs (i and j) were stained with H&E (a, c,
e, g and i) and for ASCL1 (b, d, f, h and j). Note that grade II DA, grade III AA, secondary GBM but not Primary GBM samples are
positive for ASCL1 staining
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Discussion
In the present study, we used cDNA arrays to identify
differentially expressed genes between normal brain
tissue and astrocytoma as well as between different
grades of astrocytoma. Many of the identified genes
have known or suspected relevance to cancer, while
some of them have no known functions. In accordance
with previous findings, we found Osteonectin and
Vimentin to be upregulated in the majority of all grades
of astrocytoma (Sallinen et al., 2000; Ljubimova et al.,
2001; Fathallah-Shaykh et al., 2002). Although differ-
ential regulation of b2-microglobulin has been reported
in diffuse large-B-cell lymphoma (Jordanova et al.,
2003) and multidrug resistance phenotype in tumor cells
(Scheffer et al., 2002), we found b2-microglobulin to be
upregulated in GBM. Another gene, Semaphorin 4D,
which has a functional role in the immune system
(Hall et al., 1996) as well as in the nervous system
(Kumanogoh et al., 2002), is found to be downregulated
in astroctyomas. However, the significance of its regu-
lation in astrocytomas is not known. More importantly,
we identified ASCL1 as a differentiating marker between
secondary and primary GBM. Furthermore, ASCL1
upregulation and inhibition of Notch signaling were
seen in grade II DA, grade III AA and secondary
Table 1 ASCL1 expression characterizes progressive astrocytoma
S no. Sample ID Age of
patient
Duration of
symptoms (in months)
MIB-LI (%) IHC staining Quantitative RT–PCR of ASCL1
p53 EGFR ASCL1 Status Fold change
IV, Primary GBM
1 95 55 3 10 + +  k 1.95
2 122 61 2 16  +  k 12.86*
3 242 57 1 20  + + 2 1.98
4 64 67 1 18.5 + +  k 67.68
5 65 70 6 18.5 + + + m 5.49
6 81 45 3 16.5  +  2 1.47
7 61 50 3 18.5  +  2 1.02
8 258 46 3 21  + + m 6.27
9 75 25 0.5 32 + +  k 59.72
10 156 53 3 16  + + m 4.44
11 94 58 3 18  + + 2 1.21
12 110 43 4 11.5 + +  m 2.65
IV, Secondary GBM
1 146 35 2 40 + + + m 15.99
2 195 43 3 28 +  + m 3.16*
3 197 18 4 13 +   m 4.02
4 251 35 5 28 +  + m 2.05
5 254 48 5 14 +  + m 3.04
6 255 18 6 25 + + + 2 1.64
7 160 40 5 15.5 +  + m 3.41
8 210 29 12 12  + + m 5.78
III, AA
1 79 32 5 9.8 +  + m 2.35
2 90 55 12 6 +   m 7.70
3 93 49 3 5.5 +  + m 18.27
4 140 25 1 7 +  + m 3.44
5 172 21 10 8 +  + m 5.54
6 184 28 4 9.5  + + 2 1.62
7 246 30 3.5 6 +  + m 2.10
8 259 32 12 6 +  + m 6.34
9 277 30 3 10 +  + m 11.42
10 262 35 6 9 + + m 10.21
II, DA
1 91 33 5 3 +  + m 2.43
2 127 32 2 4 +  + k 2.16*
3 248 30 24 1.5 +  + m 3.38
4 230 27 3 2 +   m 13.47
5 263 43 5 3 +  + m 15.46
6 271 13 3 1.5   + m 9.78
7 234 28 11 3   + m 2.29
MIB-LI¼MIB-1 labeling index; EGFR¼ epidermal growth factor receptor; ASCL1¼Achaete-scute complex-like 1. *Value was derived from
semiquantitative RT–PCR. mUpregulated with respect to normal brain. kDownregulated with respect to normal brain.2No significant change
with respect to normal brain
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GBMs, but not in primary GBMs, suggesting that these
molecular changes may characterize progressive astro-
cytoma.
We provide evidence for the regulation of Notch
signaling pathway during low-grade astrocytoma deve-
lopment from normal astroglial cells and further
progression to AA and then to secondary GBM. During
the development of CNS, the neural stem cells, which
are common progenitor cells, proliferate and subse-
quently differentiate into three major cell types of the
brain: neurons, astrocytes and oligodendrocytes (Qian
et al., 2000). Several molecular mechanisms have been
found to be involved in the differentiation of multi-
potent neural stem cells into different brain cell types.
Neurogenic bHLH transcription factors like neurogenin
1/2 and Mash1, a murine homolog of ASCL1, have been
shown to inhibit glial differentiation (Furukawa et al.,
2000; Zhou et al., 2000; Nieto et al., 2001; Novitch et al.,
2001; Satow et al., 2001; Sun et al., 2001). The cytokine
leukemia inhibitory factor promotes astroglial differen-
tiation through JAK-STAT signaling pathway (Johe
et al., 1996; Bonni et al., 1997). Notch signaling has been
shown to play a major role in the differentiation of
several tissues including nervous tissue in many organ-
isms (Ghysen et al., 1993; Artavanis-Tsakonas et al.,
1995, 1999). While the Notch signaling inhibits the
neuronal and oligodendroglial differentiation, it has
recently been reported to drive instructively satellite glial
cell differentiation in peripheral neural crest stem cells
and to promote astrocyte differentiation in adult
hippocampal NSCs (Morrison et al., 2000; Tanigaki
et al., 2001). Binding of any of the Notch ligands, which
include Delta1, Jagged1, and Jagged2, leads to a
complex cleavage and activation of Notch proteins
(Weinmaster, 1997; Artavanis-Tsakonas et al., 1999).
The released and activated COOH-terminal fragment of
Notch translocates to the nucleus where it interacts with
the transcription factor CBF1 (RBPjk) to transactivate
target genes including Hairy and enhancer of Split 1
(HES1) (Weinmaster, 1997; Artavanis-Tsakonas et al.,
1999). The ability of Notch ligands to activate Notch
receptor is further modulated by glycosylation of Notch
by fringe proteins (Moloney et al., 2000).
We present multiple evidences for inhibition of Notch
signaling pathway during the development of DA, which
ultimately progresses to secondary GBM. Firstly, the
level of ASCL1 transcript is found to be significantly
high in the majority of grade II/III astrocytoma as well
as secondary GBMs. Notch signaling causes transacti-
vation of HES genes, which in turn repress ASCL1
expression through transcriptional mechanisms (Chen
et al., 1997). A similar regulation is seen in HES1/
mice, where the level of ASCL1 is found to be elevated
(Ito et al., 2000). Mash1 and Math3, a murine ato
homolog, have been shown to play a major role in
neuronal versus glial fate determination in the CNS and
it is possible that downregulation of the Mash1 and
Math3 is one of the mechanisms to initiate gliogenesis
(Tomita et al., 2000). Thus, the increased level of
ASCL1 is suggestive of inhibition of Notch signaling in
progressive astrocytoma. Secondly, the transcript levels
of Notch target HES1, an inhibitor of ASCL1 expres-
sion, is not induced in the majority of grade II/III
astrocytomas and secondary GBMs in comparison to
normal brain samples. Thirdly, the levels of HES6
transcripts, a dominant-negative inhibitor of Notch
signaling, is increased several fold in the majority of
grade II/III astrocytomas and secondary GBMs. HES6
is a dominant-negative inhibitor of HES1 and it inhibits
the function of HES1 by associating with it and
abolishing its ability to repress transcription (Bae
et al., 2000; Gibert and Simpson, 2003). Finally, we
found high levels of Delta1 transcripts in most samples
analysed belonging to grade II/III astrocytoma and
secondary GBM. The reason for increased levels of
Delta1 can be explained by the fact that Delta1 is shown
to be transcriptionally activated by ASCL1 (Heitzler
et al., 1996). In fact, the expression of Delta1 appears to
be under the control of Mash1 (Post et al., 2000). Mash1
knockout is associated with a total loss of Delta1
expression in the lung (Apelqvist et al., 1999). Similarly,
MASH1 mutants fail to express Delta1 transcripts
(Casarosa et al., 1999). High levels of Notch ligand
Delta1 is capable of inhibiting Notch signaling by
forming intracellular cell-autonomus Notch :Delta1
associations (Sakamoto et al., 2002). Thus, our data
clearly demonstrate the downregulation of Notch
signaling during progressive astrocytoma development.
Our study also provides evidence for the fact that
inhibition of Notch signaling occurs only in the
secondary GBM, which is a progressive type, but not
in primary GBM, which arises by a de novo process.
While ASCL1 levels are upregulated in the majority of
grade II/III astrocytoma and secondary GBMs, its levels
remain unchanged in the majority of primary GBMs.
The expression levels of other genes associated with
Notch signaling correlate with the levels of ASCL1
expression. There are two important conclusions, we
derive from this data: (1) Inhibition of Notch signaling
pathway and the consequent upregulation of ASCL1
seem to be an early event in the development of
progressive astrocytoma as this change is seen as early
as in grade II DA. In addition, we see a continued
inhibition of Notch signaling and upregulation of
ASCL1 during the progression from grade II DA to
grade III AA and subsequently to secondary GBM.
Indeed, ASCL1 expression is reported to be tightly
linked to the NE phenotype in lung cancer. Human
ASH1 (ASCL1) was found to be selectively expressed in
normal fetal pulmonary NE cells as well as in the diverse
range of lung cancer with NE features (Ball et al., 1993;
Borges et al., 1997). However, we see an active Notch
signaling with low levels of ASCL1 in most of primary
GBMs. Thus, we conclude that inhibition of Notch
signaling is an early and perhaps also an important
event for the low-grade astrocytoma development,
which may also play a major role in further progression
into secondary GBMs. However, Notch signaling may
have no role to play in the development of primary
GBM as no change in Notch signaling is observed.
There are other pathways involved in the development
of primary GBM. For example, amplification of EGFR
Notch pathway and astrocytoma progression
K Somasundaram et al
7079
Oncogene
gene is found in 40% of primary GBMs, but it is rare in
secondary GBMs (Frederick et al., 2000). (2) Since
ASCL1 upregulation is seen in the majority of
secondary, but not in primary, GBMs. ASCL1 status
could be used as a marker to differentiate secondary
GBM from primary GBM. Mutations in p53 gene are
associated with about 50% of grade II/III astrocytomas
and secondary glioblastomas, but are seen only in
10–20% of primary glioblastoma (Campomenosi et al.,
1996; Watanabe et al., 1997; Schmidt et al., 2002). With
our finding that ASCL1 is upregulated in secondary
GBMs, combined use of ASCL1, p53 and EGFR
immunohistochemical staining to differentiate second-
ary GBMs from primary could be considered.
From our data showing a correlation between the
inhibition of Notch signaling and progressive astro-
cytoma development, we conclude that Notch signaling
may have tumor suppressor or growth inhibitory role in
astroglial cell type. Although the human Notch1 was
originally isolated as an oncogene in acute lymphoblas-
tic leukemia (Ellisen et al., 1991), this pathway has been
shown to have distinctive roles in cancers arising from
different tissues. For example, while the Notch signals
are oncogenic in pre-T cells (Ellisen et al., 1991) and
cervical epithelium (Nair et al., 2003), it suppresses
tumor development in keratinocytes (Rangarajan et al.,
2001; Nicolas et al., 2003). Since Notch signaling
promotes differentiation of neural stem cells to astro-
glial cells (Qian et al., 2000), Notch expression is likely
to be growth inhibitory rather than oncogenic in normal
astroglial cells.
Another interesting finding from this study is the
upregulation of HES6 in majority of grade II/III
astrocytoma and secondary GBMs. HES6 has been
found to be overexpressed in human primary tumors
derived from breast, lung and kidney, suggesting that
HES6 overexpression may have an oncogenic role
(Swearingen et al., 2003). Indeed, HES6 has been
located in chromosome 2q37, a region known to be
amplified in common adenocarcinomas such as that of
the lung, breast, prostate, kidney and ovary (Mitelman
et al., 2002). The ability of HES6 to inhibit HES1
activity could be significant in that Notch signaling has
tumor suppressor role in certain tissues (Rangarajan
et al., 2001; Nicolas et al., 2003) and HES1 has been
shown to play a role of tumor suppressor in mammary
gland carcinoma cells (Strom et al., 2000; Muller et al.,
2002). Taken together, our data suggest that Notch
signaling has a tumor suppressor role in astroglial cell
type and is inhibited early during the development of
low-grade astrocytoma, which may provide a suitable
environment for further development to AA and then to
secondary GBM.
Materials and methods
Tissue collection
Astrocytoma tissue samples were collected from patients who
were operated at Sri Satya Sai Institute of Higher Medical
Sciences and Manipal Hospital, Bangalore, India, at the time
of surgical resection. Control samples comprised nontumorous
brain tissue samples (temporal lobe) collected from patients
who underwent surgery for intractable epilepsy. A total of 37
astrocytoma samples of different grades were used in this
study. Tissues were bisected and one-half was snap-frozen in
liquid nitrogen and stored at 801C until RNA isolation. The
other half was fixed in formalin and processed for paraffin
sections and these were used to identify the histopathological
grade and the type of astrocytoma and further immunohisto-
chemical staining.
RNA isolation, cDNA labeling and microarray analysis
Total RNA was extracted from the frozen tissue by a
combination of the TRIzol method (Life Technologies Inc.).
and RNeasy Midi kit (Qiagen) according to the manufacturer’s
instructions. The RNA samples were quantified by measuring
the absorbance using a spectrophotometer and visualized on a
MOPS–formaldehyde gel for quality assurance. cDNA synth-
esis and labeling of total RNA were carried out using the
Micromax direct labeling kit (Perkin-Elmer Life Sciences,
Inc.). RNA derived from normal brain tissue was labeled with
Cyanine 3-dUTP, while that of tumor was labeled with
Cyanine 5-dUTP. Total RNA (20 mg) was used for each
labeling reaction. The quality of cDNA labeling was mon-
itored by separating small amounts of Cy3- and Cy5-labeled
cDNA in an agarose gel made on a microscopic slide and
scanning the gel using the laser scanner LSIV (Genomic
Solutions, USA). Cy3- and Cy5-labeled cDNAs were added to
100 ml of 1 hybridization buffer (Ultrahyb, Sigma) incubated
at 751C for 5min before adding to the GeneMap Human
Cancer Array (Genomic Solutions). Hybridization was carried
out in a GeneTAC Hyb Station (Genomic Solutions) at 651C
for 4 h, 601C for 4 h and 551C for 10 h. The slides were washed
using medium stringency, high stringency and postwash
buffers (Genomic solutions) for 5min each, dried and scanned
using the GeneTAC LS IV scanner (Genomic Solutions).
Microarray image and data analysis
Image analysis was carried out with the GeneTAC Analyzer
software, Version 3.3 (Genomic Solutions. Filtering and
assembling) of data were carried out using MS Excel and
MS Access. To begin with, the image was visually inspected
and spots of questionable quality were flagged and eliminated
from further consideration. In the next step, spots having a
signal-to-noise ratio less than 1.1 in both channels and total
intensity values below a threshold value were excluded. We
first computed arithmetic mean and s.d. for background
subtracted total intensities of all negative control spots
(3 SSC) on the slide and then computed threshold value as
arithmetic mean plus 2 s.d.’s. If the coefficient of variation of
expression ratios of duplicate spots of a given gene is greater
than 20%, then the gene was excluded from further analysis.
Normalization was carried out by median log ratio method.
The Cy5 :Cy3 normalized expression ratio was determined for
each spot and these values from the duplicate spots within each
array were averaged and log 2 transformed. All the subsequent
analysis is carried out using log 2-transformed data.
For the purpose of data analysis, the grade II and III
samples were classified into one group, while the grade IV
GBMs formed the second group. We have analysed three
grade II/III samples and four GBM samples by microarray
hybridization. Only the genes having values in at least two
samples in each group were used for further analysis. To deter-
mine the suitability of the data for further supervised analyses,
an unsupervised, two-way, average-linkage hierarchical cluster
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analysis with uncentered correlation coefficient as similarity
metric, using the Gene Cluster software, Version 2.20 (avai-
lable at http://rana.lbl.gov/EisenSoftware.htm) was carried out
(Eisen et al., 1998). The Java TreeView software, Version 0.9.4
(available at http://genetics.stanford.edu/Balok/) was used to
display and analyse the results of the Gene Cluster program.
The objective was to see if samples of same pathological grade
cluster together. Clustering was also carried out to visualize the
structure of the data and different patterns of gene expression.
Real-time RT–PCR
The relative quantitation of expression levels of selected genes
was carried out using two step strategy: in the first step, cDNA
was generated from RNA derived from different tissue samples
using cDNA Archive kit (ABI PRISM); subsequently, real-
time quantitative PCR was carried out in ABI PRISM 7000/
7900 (Applied Biosystems) sequence detection system with
the cDNA as template using gene-specific primer sets and
DyNAmoTM HS SYBRs Green qPCR kit (Finnzymes,
Finland). Data were analysed as per the relative quantification
model proposed by Pfaffl, which includes efficiency correction
(Pfaffl, 2001). All measurements were made in duplicate, and
for each qRT–PCR primer set, reaction efficiency estimates
were derived from standard curves that were generated using
serial dilutions of the pool of cDNA set used for the study.
Ribosomal protein L35a was used as internal control as its
expression level was found to be unaltered in the array
experiments. Normal brain tissue samples from four different
epilepsy patients were used as reference. An increase or
decrease in gene expression by two fold or more over its mean
expression in reference samples, unless stated otherwise, was
considered significant. For certain samples, data were obtained
by semiquantitative RT–PCR. PCR primer sequences, and
conditions used will be provided on request.
Immunohistochemistry
Paraffin sections (5 mm) from the tumor and control tissues
were collected on chrome–alum coated slides and subjected for
immunohistochemistry using the streptavidin–biotin complex/
immunoperoxidase method using the following monoclonal/
polyclonal antibodies: MIB-1 (Ki-67 monoclonal antibody,
DAKO, Denmark; 1 : 50); p53 (DO-1, Oncogene; 1 : 100);
EGFR (Oncogene, 1 : 25); ASCL1 (Polyclonal, SIGMA;
1 : 50). Briefly, 5mm paraffin sections were deparaffinized in
xylene, dehydrated in graded alcohol series and rinsed in Tris
buffer (50mM, pH 7.6) for 15min. The sections were then
microwaved for 15–20min at 700W in sodium citrate buffer
(10mM, pH 6.0) to retrieve antigenicity from paraffin sections.
For EGFR staining, the sections were pretreated with 0.05%
trypsin at 371C for 30min. All sections were further treated
with methanol and 3% hydrogen peroxide to block endogen-
ous peroxidase followed by washes with Tris buffer. Milk
powder (3%) or bovine serum albumin was used to block
background staining for 30min. The sections were then
incubated with the primary antibody for 2 h followed by the
linked streptavidin-biotinylated secondary antibody (Univer-
sal LSAB, DAKO). 303-diaminobenzidine (Sigma) was used as
the chromogenic substrate.
Brain tumor samples previously characterized for over-
expression of p53 and EGFR were used as positive controls.
For ASCL1, the tumor sample, which showed marked
upregulation by RT–PCR, was taken as the positive control.
A negative control slide in which the primary antibody was
excluded was used with each batch of slides. For MIB-1 and
p53 immunostaining only nuclear staining was regarded as
positive, whereas with EGFR, positive sample showed
cytoplasmic and cell surface membrane staining.
For ASCL1 immunostaining, only nuclear staining was
considered as positive signal. Tumors were considered ASCL1
positive when more than 5% of tumor cells showed nuclear
staining. Regarding p53 and EGFR also, specimens with less
than 5% immunopositive tumor cells were scored as negative.
The MIB-1 labeling index (LI) was expressed as the percentage
of tumor cell nuclei stained, in areas of maximum staining and
calculated in at least 1000 tumor cells.
MIB-1 LI was used for accurate grading of astrocytomas.
The mean cutoff LI for grade II astrocytomas was 2.147
1.042%; 7.6871.786% for grade III AA; and 19.677.578%
for GBM, which more or less corresponded to mean values
laid down by the WHO grading scheme (Kleihues et al., 2000).
GBMs were classified as primary or secondary taking into
consideration the clinical profile of patients, expression of p53
and EGFR. The mean age of patients with primary GBMs was
50.6 years and mean duration of symptoms was 2.7 months.
All tumors showed highly pleomorphic, histomorphological
features and evidence of ‘field necrosis’. Uniform staining for
EGFR by immunohistochemistry was evident in all cases and
five revealed additionally p53 expression. Among secondary
GBMs, the mean age of the patients was 33.8 years and mean
duration of symptoms was 5.3 months. p53 immunoreactivity
was uniformly evident in all cases and two revealed addition-
ally EGFR overexpression. Histological evidence of progres-
sion from grades II or III astrocytoma was clearly seen in 5/8
cases. The details are given in Table 1.
Abbreviations
ASCL1, Achaete-scute complex-like 1 (Drosophila); GBM,
glioblastoma multiforme; HES1, Hairy and Enhancer of Split
1; HES6, Hairy and Enhancer of Split 6; DA, diffuse
astrocytoma; AA, anaplastic astrocytoma.
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